Rafael Holdings, Inc. announced its results of operations for the fiscal quarter ended April 30, 2026, via an earnings release on June 11, 2026. The company is a provider of technology and services in the technology sector.

Rafael Holdings, Inc. announced that the last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C. Topline data from the main study cohort is expected to be announced in the second half of 2026. Rafael Holdings, Inc. is a biotechnology company focused on developing therapeutic treatments for rare diseases.